Mr. Elam is a native of Silicon Valley who has been managing and advising healthcare and technology companies for more than 30 years.

Prior to founding Rezolute, Mr. Elam served in various senior leadership roles at different organizations including as Head of the Pulmonary Business Unit at Nektar Therapeutics (NASDAQ: NKTR). During his tenure at Nektar, he was instrumental in streamlining the organization and reshaping its pipeline. Prior to negotiating the sale of his division to Novartis, Mr. Elam spun two entities out of Nektar, including Aerogen in Galway Ireland and Pearl Therapeutics which was acquired by AstraZeneca for $1 billion. Earlier in his career, Mr. Elam was CFO and co-founder of a web-based IT platform company serving the electronics and healthcare industries where, in addition to managing finance and business development, he established operations in the US as well as throughout Asia.

In the 1990s, Mr. Elam was a corporate partner at the law firm of Wilson Sonsini Goodrich & Rosati, where he advised domestic and ex-US healthcare and technology companies on various matters from debt and equity financings to licensing and cross-border transactions. His clients included emerging growth companies as well as mature corporations such as Genentech and Hewlett Packard. Notably, he represented Steve Jobs’ company, Next and negotiated the sale of Next to Apple.

Throughout his career, Mr. Elam has served on the board of directors of various healthcare companies in the US, Europe and Asia. He currently serves on the board of Savara, Inc. (NASDAQ:SVRA) in Austin Texas as well as on the board of Rezolute.

Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.